Hoshi, Taisuke <br/><br/>
Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.  [electronic resource] 

 -  Biochemical and biophysical research communications  05 2019 
 - 1-7 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1090-2104 
<br/><br/><label>Standard No.: </label>10.1016/j.bbrc.2019.02.015  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--therapeutic use<br/>Carcinoma, Hepatocellular--drug therapy<br/>Cell Line, Tumor<br/>Female<br/>Fibroblast Growth Factors--metabolism<br/>Humans<br/>Liver Neoplasms--drug therapy<br/>MAP Kinase Signaling System--drug effects<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, Nude<br/>Phenylurea Compounds--therapeutic use<br/>Quinolines--therapeutic use<br/>Receptors, Fibroblast Growth Factor--metabolism<br/>Signal Transduction--drug effects